LEXINGTON, Mass., Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:
AGEN), an immuno-oncology company with an extensive pipeline of
agents that activate immune response to cancers, is pleased to
announce the appointment of Dr. Jennifer
Buell to President and COO.
"Jen's tenure with Agenus, her exceptional leadership and
cultural attributes, and her deep understanding of our science and
operations makes her the top candidate for this newly created
position," said Garo H. Armen,
Ph.D., Chairman and CEO of Agenus. He added, "I am very excited to
partner with Jen as we set to realize Agenus' vision of defeating
cancer in the coming years."
After her tenure at Harvard Clinical Research Institute, Dr.
Buell rejoined Agenus in 2013 as the Head of Global R&D
operations. She was subsequently appointed as Chief Communications
and External Affairs Officer, and then, to the position of Chief
Operating Officer.
Dr. Buell brings over 20 years of biopharmaceutical industry
experience and knowledge. Her efforts in the rapid advancement of
discovery candidates through development has resulted in Agenus'
record of advancing 13 I-O candidates to the clinic in the past
four years. Her experience also includes extensive communication
with internal and external constituencies, regulators, investors,
and collaborators. Dr. Buell's previous operational and research
experience include her tenures at Bristol-Myers Squibb and Harvard
Clinical Research Institute. Dr. Buell obtained her PhD in
Cellular, Biochemical, and Molecular Biochemistry with an MS in
Biostatistics from Tufts University in
Boston.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, proprietary cancer vaccine platforms, and
adoptive cell therapies (through its AgenTus Therapeutics
subsidiary). The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' clinical
development plans and timelines, the vision of defeating cancer in
the coming years, and the expected contributions of Dr. Buell.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus Inc.
Regina Grebla, PhD
VP, Investor Relations & Communications
781-674-4495
regina.grebla@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-announces-the-appointment-of-dr-jennifer-buell-to-the-position-of-president-and-coo-300984430.html
SOURCE Agenus Inc.